CTLA-4 blocking mAbs are approved for the treatment of HCC, NSCLC, melanoma, renal cell carcinoma, mesothelioma, CRC, and cutaneous squamous cell carcinoma [55,56]. The gene discussed is CTLA4; the disease is melanoma.